ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2011, 'Long-term neuropathy after Oxaliplatin treatment: Challenging the dictum of reversibility', Oncologist, 16, pp. 708 - 716, http://dx.doi.org/10.1634/theoncologist.2010-0248
,2011, 'Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 29, pp. e553 - e554e
,2011, 'Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.', British Journal of Cancer, 105, pp. 1144 - 1150
,2011, 'Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.', Breast Cancer Research and Treatment, 130, pp. 1057 - 1061
,2011, 'Rethinking ovarian cancer: recommendations for improving outcomes.', Nature Reviews Cancer, 11, pp. 719 - 725, http://dx.doi.org/10.1038/nrc3144
,2011, 'The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.', Asia-Pacific Journal of Clinical Oncology, 7, pp. 197 - 211
,2011, 'Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy', Experimental Neurology, 227, pp. 120 - 127, http://dx.doi.org/10.1016/j.expneurol.2010.10.002
,2010, 'Analysis of candidate genes for macular telangiectasia type 2', Molecular Vision, 16, pp. 2718 - 2726
,2010, 'The future is 'PARP' - Phase-II-activity of PARP inhibitor among patients with BRCA-deficient breast cancer', Breast Care, 5, pp. 364 - 365, http://dx.doi.org/10.1159/000322170
,2010, 'The ATAC adjuvant breast-cancer trial: Six-year results of the endometrial subprotocol', JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 30, pp. 596 - 604, http://dx.doi.org/10.3109/01443615.2010.492433
,2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial', The Lancet, 376, pp. 235 - 244, http://dx.doi.org/10.1016/S0140-6736(10)60892-6
,2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial', The Lancet, 376, pp. 245 - 251, http://dx.doi.org/10.1016/S0140-6736(10)60893-8
,2010, 'Influence of fatigue after breast cancer adjuvant theraphy on health care utilization and percieved needs', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.9047
,2010, 'Erratum: Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the kathleen cuningham foundation consortium for research into familial breast cancer (kConFab) (Breast Cancer Res Treat (2010) (120) DOI: 10.1007/s10549-009-0497-8))', Breast Cancer Research and Treatment, 120, pp. 725 - 726, http://dx.doi.org/10.1007/s10549-009-0528-5
,2010, 'Current academic clinical trials in ovarian cancer: Gynecologic cancer intergroup and us national cancer institute clinical trials planning meeting, may 2009', International Journal of Gynecological Cancer, 20, pp. 1, http://dx.doi.org/10.1111/IGC.0b013e3181ee1c01
,2010, 'Malignant transformation within ovarian dermoid cysts: An audit of treatment received and patient outcomes. An Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study', International Journal of Gynecological Cancer, 20, pp. 75 - 81, http://dx.doi.org/10.1111/IGC.0b013e3181c7fccf
,2010, 'Optimally debulked stage III ovarian cancer: intraperitoneal or intravenous chemotherapy?', International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 20, http://dx.doi.org/10.1111/igc.0b013e3181f60d26
,2010, 'The international testicular cancer linkage consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred', Urologic Oncology: Seminars and Original Investigations, 28, pp. 492 - 499, http://dx.doi.org/10.1016/j.urolonc.2008.10.004
,2010, '5. A novel biomarker of axonal dysfunction in oxaliplatin-induced neurotoxicity', Clinical Neurophysiology, 121, pp. e2 - e2, http://dx.doi.org/10.1016/j.clinph.2009.10.025
,2010, 'A phase 11, open-label study evaluating pazopanib in patients with recurrent ovarian cancer', Gynecologic Oncology, 119, pp. 32 - 37
,2010, 'Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change', International Journal of Gynecological Cancer, 20, pp. 664 - 684
,2010, 'Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for research into familial breast cancer', Breast Cancer Research and Treatment, 120, pp. 715 - 723
,2010, 'Malignant transformation within ovarian dermoid cysts:and audit of treatment received and patient outcomes', International Journal of Gynecological Cancer, 20, pp. 75 - 81
,2010, 'Moving towards personalised medicine: Treatment- focused genetic testing of women newly diagnosed with ovarian cancer.', International Journal of Gynecological Cancer, 20, pp. 704 - 716, http://dx.doi.org/10.1111/IGC.0b013e3181dbd1a5
,2010, 'Optimally debulked stage 111 ovarian cancer: intraperitoneal or intravenous chemotherapy?', International Journal of Gynecological Cancer, 20, pp. S20 - S23
,2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-content trial', The Lancet, 24, pp. 235 - 244
,2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proff-of-concept trial.', The Lancet, 24, pp. 245 - 251
,2010, 'Predictors of breast cancer screening behaviors in women with a strong family history of the disease.', Breast Cancer Research and Treatment, 124, pp. 509 - 519, http://dx.doi.org/10.1007/s10549-010-0868-1
,2009, 'Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor', European Journal of Cancer, 45, pp. 3262 - 3270, http://dx.doi.org/10.1016/j.ejca.2009.05.030
,2009, 'Younger age-at-diagnosis for familial malignant testicular germ cell tumor', Familial Cancer, 8, pp. 451 - 456, http://dx.doi.org/10.1007/s10689-009-9264-6
,2009, 'Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 361, pp. 766 - 776, http://dx.doi.org/10.1056/nejmoa0810818
,2009, 'Article on Reproductive Factors and Mortality after Breast Cancer (vol 18, pg 1792, 2009)', CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 18, pp. 2345 - 2345, http://dx.doi.org/10.1158/1055-9965.EPI-18-8-CORI
,2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', Journal of Clinical Oncology, 27, pp. CRA501 - CRA501, http://dx.doi.org/10.1200/jco.2009.27.18s.cra501
,2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', Journal of Clinical Oncology, 27, pp. CRA501 - CRA501, http://dx.doi.org/10.1200/jco.2009.27.18_suppl.cra501
,2009, 'Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)', Journal of Clinical Oncology, 27, pp. 1509 - 1509, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.1509
,2009, 'Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer', Journal of Clinical Oncology, 27, pp. 5500 - 5500, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5500
,2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', Journal of Clinical Oncology, 27, pp. CRA501 - CRA501, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.cra501
,2009, 'Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer intergroup', Journal of Clinical Oncology, 27, pp. 1419 - 1425, http://dx.doi.org/10.1200/JCO.2008.19.1684
,2009, 'Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer', European Journal of Cancer, 45, pp. 551 - 560, http://dx.doi.org/10.1016/j.ejca.2008.09.023
,2009, 'Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium', British Journal of Cancer, 100, pp. 412 - 420, http://dx.doi.org/10.1038/sj.bjc.6604820
,2009, 'Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial', Annals of Oncology, 20, pp. 1489 - 1498, http://dx.doi.org/10.1093/annonc/mdp033
,2009, 'Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer.', International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 19 Suppl 2, http://dx.doi.org/10.1111/igc.0b013e3181bf7fb8
,2009, 'The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: Results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up', Annals of Oncology, 20, pp. 1344 - 1351, http://dx.doi.org/10.1093/annonc/mdp024
,2009, 'Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 27, pp. 1243 - 1249
,2009, 'Breast cancer in young women and its impact on reproductive function', Human Reproduction Update, 15, pp. 323 - 339, http://dx.doi.org/10.1093/humupd/dmn064
,2009, 'Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry', Breast Cancer Research and Treatment, 117, pp. 167 - 176
,2009, 'Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials', Journal of Clinical Oncology, 27, pp. 5109 - U194
,2009, 'Oxaliplatin-induced Lhermitte’s phenomenon as a manifestation of severe generalized nerve dysfunction', Oncology, 77, pp. 342 - 348
,2009, 'Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy', Brain, 132, pp. 2712 - 2723
,2009, 'Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry', Cancer epidemiology biomarkers and prevention, 18, pp. 1792 - 1797
,